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Abstract
Weil’s disease caused by Leptospira species is characterized by impaired 
hepatic and renal function. We report a 71-year-old man with Weil’s dis-
ease associated with Epstein-Barr Virus (EBV). The patient was admitted 
because of progressive jaundice for 1 week. EBV infection and leptospiro-
sis were determined by serologic tests. After treatment with intravenous 
penicillin and minocycline, the jaundice subsided. Immunosuppression 
during active EBV infection has been reported previously, and therefore, 
this could have caused the severe symptoms after Leptospira infection in 
our case. [Tzu Chi Med J 2010;22(1):47–49]
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1. Introduction
Leptospirosis is a zoonotic disease caused by 
Leptospira, which comprises 24 serogroups and 250 
serovars, and is transmitted to humans by direct or 
indirect exposure to urine or other body fluids of in-
fected animals [1,2]. Although considered to be the 
most geographically widespread zoonosis, it is restricted 
to some occupational groups with a high exposure 
risk such as farmers, miners, abattoir workers and 
sewer workers [1,2]. The clinical presentation in hu-
mans ranges from a mild flu-like illness to a severe 
illness with jaundice, meningitis, renal failure, pulmo-
nary hemorrhage and, occasionally, death.
Weil’s disease caused by Leptospira species is 
characterized by impaired hepatic and renal function. 
Mortality rates range from 5% to 40% [1–4]. More 
than 60% of serologically identified infections 
are asymptomatic [5,6]. Epstein-Barr virus (EBV) can 
induce complex humoral and cell-mediated immune 
responses in humans, which impair liver function 
[7,8]. Weil’s disease associated with active EBV in-
fection has not been reported previously.
2. Case report
A 71-year-old man was admitted because of a 1-week 
history of general malaise. The patient was a farmer 
who had a 35-year history of consumption of 100–
200 mL rice wine, once or twice per week. He had 
been in good health until 1 week prior to admission. 
Examination at admission revealed tea-colored urine 
in addition to general malaise. The patient had no 
history of travel and had not taken any medicine in 
the previous year.
The patient’s body temperature was 36ºC, blood 
pressure was 137/92 mmHg, heart rate was 71 beats 
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per minute and respiratory rate was 18 cycles per 
minute. Physical examination showed that his skin and 
sclera were icteric, but there were no infected throat, 
lymphadenopathy, splenomegaly, edema or Kayser-
Fleischer rings. A hemogram showed a leukocyte 
count of 17,310/mL with 93% segmented neutrophils, 
a hemoglobin level of 11.8 g/dL, and a platelet count 
of 34,000/mL. Prothrombin and activated partial 
thromboplastin times were 10.9 and 32.6 seconds, re-
spectively (reference values, 10 and 10.9 seconds, re-
spectively). Electrolyte levels were within normal limits. 
Serum aspartate aminotransferase level was 332 IU/L, 
alanine aminotransferase level was 188 IU/L, total bi-
lirubin was 33 mg/dL, direct bilirubin was 21.6 mg/dL, 
lactate dehydrogenase was 641 IU/L, total protein was 
6.6 g/dL, albumin was 2.68 g/dL, alkaline phosphatase 
was 242 IU/L, γ-glutamyl transpeptidase was 200 IU/L, 
urea nitrogen was 66 mg/dL, creatine was 1.0 mg/dL 
and C-reactive protein was 27.22 mg/dL. Abdominal 
sonography and computed tomography showed mild 
splenomegaly without other specific findings.
The patient was treated with parenteral ceftriaxone 
(2 g every 12 hours). Bilirubin levels increased despite 
treatment (total bilirubin was 55.7 mg/dL; direct bi-
lirubin was 38 mg/dL). Serum antibodies against hep-
atitis A and serum surface antigen of hepatitis B were 
negative. Serum antibodies against hepatitis C were 
positive but hepatitis C RNA was undetectable with 
polymerase chain reaction. EBV serum immunoglobin 
G and M were positive, while serum immunoglobin 
against EBV nuclear antigen was negative. Two blood 
cultures were negative.
Despite ceftriaxone treatment, leukocytosis and 
jaundice persisted. The antibiotic regimen was changed 
to parenteral penicillin G (3 MU every 6 hours) and 
parenteral minocycline (100 mg every 12 hours) on 
day 5 of hospitalization. A microscopic agglutination 
test using serum antibodies against Leptospira santa-
rosai serovar shermani, L. borgpetersenii serovar 
poi, and L. tarassovi performed at the Taiwan Center 
for Disease Control revealed a greater than four-fold 
increase in paired serum samples (Table 1). Jaundice 
and leukocytosis progressively subsided and the pa-
tient was discharged after 3 weeks. During the sub-
sequent 11 months, mild jaundice in the absence of 
specific discomfort was observed.
3. Discussion
Seroprevalence studies support the view that sub-
clinical leptospirosis infections are common world-
wide. More active surveillance leads to an increased 
detection of human cases [9]. In general, the diagnosis 
is initially based on clinical suspicion, and is confirmed 
later by laboratory results, usually by the detection of 
specific antibodies using the microscopic agglutination 
test. In our case, EBV infection and leptospirosis were 
confirmed by serologic methods. Cross-reactivity be-
tween these serologic tests does not occur [10]. EBV 
infection is typically acquired during the childhood or 
teenage years; over the age of 40, the infection rate 
is 2–10% [11]. The frequency with which adults older 
than 40 years old develop clinically overt disease is un-
known because of the low rate of susceptibility in this 
age group. However, many elderly patients with acute 
EBV have been reported [12–15]. In the present case, 
acute EBV infection was likely, given the absence of 
serum immunoglobin to EBV nuclear antigen. Un-
fortunately, the possibility of a false negative could 
not be excluded because of the lack of paired serum. 
The results of EBV serological testing indicated that 
reactivation of EBV was still possible.
The pathogenesis of leptospirosis involves diffuse 
vasculitis. The clinical presentation in most patients 
is mild and self-limited, but uncommonly severe Weil’s 
disease characterized by hepatic impairment is man-
ifest. The pathogenesis of jaundice is disorganized 
and can involved Leptospira-mediated obliteration of 
the sinusoids [16]. In patients infected with EBV, the 
major hepatic manifestation is a self-limited elevation 
in hepatocellular enzyme levels [8]. Minimal swelling 
and vacuolization of hepatocytes, pleomorphic lym-
phocytic and monocytic portal infiltrations and mini-
mal swelling of the bile ducts are evident, and biliary 
stasis is rare [17]. Less commonly, those over 40 years 
old can develop peripheral lymphadenopathy, phar-
yngitis, and splenomegaly and, unlike young adults, 
have a more prolonged fever, liver involvement and 
jaundice [11–15].
Disease determinants for leptospirosis are presum-
ably related to exposure that influences the inoculum 
size during infection and host factors [5,18]. An im-
portant epidemiological question is as follows: why do 
certain exposed individuals develop mild symptomatic 
infections, while others progress to develop Weil’s dis-
ease? In patients with self-limited leptospirosis, a spi-
rochetemic phase is generally followed by an immune 
phase. During the immune phase, organisms disap-
pear from the blood [19]. Immunity for leptospirosis 
may be antibody-mediated since Leptospira are extra-
cellular pathogens and protection can be passively 
transferred in hamsters [20]. When monocytes are 
stimulated with lipopolysaccharide or phorbolmyristate 
acetate, two strong inducers of tumor necrosis factor-α 
expression, EBV inhibits stimulus-induced liberation of 
Table 1 — Change in serum antibody titers against 
Leptospira species in paired serum samples
Leptospira species Day 4 Day 18
Leptospira santarosai serovar shermani 1:400 1:6400
L. borgpetersenii serovar poi 1:200 1:6400
L. tarassovi 1:200 1:3200
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70–90% of tumor necrosis factor-α, which participates 
in regulation, maturation, activation and proliferation 
of B and T lymphocytes [21–23]. These EBV immu-
nosuppressive effects may delay antibody-mediated 
immunity to Leptospira, and prolonged survival of 
Leptospira increases the chances of sinusoid oblit-
eration. Weil’s disease caused by Leptospira may be 
attributable to immunosuppression caused by active 
EBV infection.
Although immunosuppression occurs in patients 
with active EBV infection, coinfection with other 
pathogens has seldom been reported. Chlamydophila 
pneumoniae coinfection with EBV has been de-
scribed [24]. Rickettsioses and malaria coinfection 
with Leptospira have been demonstrated with similar 
epidemiological profiles and clinical presentations 
[25,26]. In clinical practice, EBV serology is typically 
carried out when a patient presents with infectious 
mononucleosis. However, elderly patients with active 
EBV rarely display the classical triad of acute EBV in-
fection. Active EBV infection is rarely considered when 
a patient presents with jaundice or other symptoms 
that are considered to be caused by another patho-
gen. EBV infection in elderly patients may thus be 
underestimated or even ignored. Clinical studies are 
needed to clarify whether EBV-mediated immuno-
suppression influences the severity of other infectious 
diseases.
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